Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in lymphoma
- Trial result
Lymphoma
Liso-cel (CD19 CAR-T) Delivers 100% CR/ORR With Minimal CRS/Neurotoxicity in Japanese R/R FL
Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed CAR-T cell therapy evaluated in the Japanese subgroup of the Phase 2 TRANSCEND FL study (NCT04245839) in second-line or later relapsed/refractory…
NCT04245839 - Trial result Spotlight
Lymphoma
Glofitamab (CD3×CD20) + pola-R-CHP (CD79b ADC + anti-CD20 chemoimmunotherapy) drives 95% CR and 95% 24‑mo PFS in high-risk 1L DLBCL
Glofitamab is a CD3×CD20 T-cell–engaging bispecific antibody added to polatuzumab vedotin (CD79b ADC) plus R-CHP chemotherapy (rituximab, cyclophosphamide, doxorubicin, prednisone) in a multicenter Phase II frontline…
NCT05800366 - Trial result Spotlight
Lymphoma
Pembrolizumab-GVD followed by autologous transplantation shows 91% five-year PFS in relapsed/refractory classical Hodgkin lymphoma
Pembrolizumab-GVD combines pembrolizumab (anti–PD-1) with gemcitabine/vinorelbine/liposomal doxorubicin chemotherapy as PET-adaptive salvage to bridge transplant-eligible relapsed/refractory classical Hodgkin…
NCT03618550 - Trial result
Lymphoma
Favezelimab (anti–LAG-3) + pembrolizumab (PD-1) reports 83% ORR in PD-1–naive R/R cHL; development discontinued
Favezelimab (MK-4280) is an anti–LAG-3 monoclonal antibody designed to deepen checkpoint blockade when combined with pembrolizumab (anti–PD-1); this Phase 1/2 MK-4280-003 cohort enrolled anti–PD-1–naive…
NCT03598608 - Trial result
Lymphoma
Mosunetuzumab (CD20xCD3 bispecific) + response-adapted polatuzumab vedotin (CD79b ADC) drives 86% PET-CR and 89% 2y PFS in untreated indolent NHL
Mosunetuzumab is an IV CD20xCD3 T-cell–engaging bispecific antibody; polatuzumab vedotin is a CD79b-directed antibody–drug conjugate, and obinutuzumab is a type II anti-CD20 mAb. In this single-arm, response-adapted…
- New trial Spotlight
Lymphoma
Phase 2 BOSon tests zanubrutinib + obinutuzumab + sonrotoclax in frontline MCL
Memorial Sloan Kettering Cancer Center is running this Phase 2 study of a chemotherapy-free, MRD-guided frontline regimen for transplant-ineligible patients with stage II–IV mantle cell lymphoma. Treatment combines…
NCT07799220 Exploratory - New trial
Lymphoma
Phase 2 epcoritamab CD3×CD20 bispecific T‑cell engager vs watchful waiting in low‑burden FL.
This randomized Phase 2 study at MD Anderson Cancer Center tests whether starting epcoritamab earlier can delay the need for conventional lymphoma therapy in previously untreated, low tumor burden follicular lymphoma…
NCT07783594 Exploratory - Trial result
Lymphoma
Favezelimab (LAG-3 mAb) + pembrolizumab (PD-1) posts 29% ORR in PD-1–refractory cHL
Favezelimab is an anti–LAG-3 monoclonal antibody designed to deepen checkpoint blockade when combined with pembrolizumab (anti–PD-1). In the open-label MK-4280-003 Phase 1/2 study (NCT03598608), anti–PD-1–refractory…
NCT03598608 - New trial Spotlight
Lymphoma
Phase 2 teclistamab BCMA×CD3 T‑cell–redirecting bispecific antibody in R/R Waldenström’s macroglobulinemia.
This single-group, open-label Phase 2 study evaluates teclistamab (a BCMA×CD3 bispecific monoclonal antibody that redirects T cells to kill BCMA-expressing malignant B-lineage cells) in relapsed or refractory…
NCT07791498 Exploratory - Trial result Spotlight
Lymphoma
BV (CD30-directed ADC) + nivolumab (PD-1) + limited chemo delivers 97% 2-year PFS in nonbulky early-stage cHL (SGN35-027)
Brentuximab vedotin (BV) is a CD30-targeted antibody–drug conjugate and nivolumab is a PD-1 checkpoint inhibitor; in SGN35-027 Part C (Phase 2; NCT03646123), previously untreated Ann Arbor stage I–II nonbulky…
NCT03646123 - Trial result
Lymphoma
Epcoritamab (CD3×CD20) + R² Drives 95% ORR in Frontline Follicular Lymphoma—But Infection Risk Looms
Epcoritamab is a subcutaneous CD3×CD20 T-cell–engaging bispecific antibody, here added to the chemotherapy-free backbone of rituximab + lenalidomide (R²) as first-line therapy. In the open-label, multicentre EPCORE…
NCT04663347 - New trial
Lymphoma
Phase 2 tafasitamab CD19 cytolytic mAb + rituximab CD20 mAb in untreated follicular lymphoma
This University of Washington–sponsored Phase 2, single-arm study (with Incyte Corporation collaboration) tests whether adding tafasitamab to rituximab can deepen first-remission quality in newly diagnosed follicular…
NCT07731789 Exploratory - Trial result Spotlight
Lymphoma
Epcoritamab (CD3×CD20 bispecific) + R-CHOP Drives 85% CR and 80% 2-year PFS in High-Risk Newly Diagnosed LBCL
Epcoritamab is a subcutaneous CD3×CD20 bispecific T-cell–engaging antibody added to standard R-CHOP, aiming to deepen frontline remissions in CD20+ large B-cell lymphoma (LBCL). In Arm 1 of the Phase 1b/2 EPCORE…
NCT04663347 - Trial result
Lymphoma
Glofitamab (CD20×CD3 bispecific) + G/R-CHOP drives 83.9% complete metabolic responses in R/R B-cell NHL
Glofitamab is an IV CD20×CD3 T-cell–engaging bispecific antibody; here it was combined with obinutuzumab/rituximab plus CHOP (G/R-CHOP) in a Phase 1b dose-escalation study in relapsed/refractory B-cell non-Hodgkin…
NCT03467373 - Trial result
Lymphoma
Nivolumab (PD-1) + AVD Delivers 2-year PFS ~78% in HIV-Associated Advanced cHL (S1826 subset)
Nivolumab is a PD-1 checkpoint inhibitor combined here with AVD chemotherapy (doxorubicin, vinblastine, dacarbazine) and was tested against brentuximab vedotin (CD30-directed ADC) + AVD in the international Phase 3…
NCT03907488 - Trial result Spotlight
Lymphoma
Epcoritamab (CD3×CD20 bispecific) + BR delivers 96% CR and 83% 3-year PFS in 1L follicular lymphoma
Epcoritamab is a subcutaneous CD3×CD20 T-cell–engaging bispecific antibody; in EPCORE NHL-2 arm 3 (Phase 1b/2; NCT04663347), it was combined with first-line bendamustine+rituximab (BR) followed by epcoritamab…
NCT04663347 - New trial Spotlight
Lymphoma
Phase 2/3 MK-1045 CD19×CD3 bispecific antibody plus rituximab (CD20 mAb) in 1L FL.
Merck Sharp & Dohme (MSD) is running a Phase 2/3, randomized, open-label study testing MK-1045 + rituximab (or a rituximab biosimilar) versus physician’s choice chemoimmunotherapy in previously untreated classical…
NCT07634471 Registrational - New trial
Lymphoma
Phase 1b teclistamab BCMA×CD3 bispecific T‑cell engager in relapsed/refractory plasmablastic lymphoma.
This Phase 1b, open-label, dose-finding and expansion study sponsored by the National Cancer Institute evaluates subcutaneous teclistamab for patients with relapsed/refractory plasmablastic lymphoma after at least 1…
NCT07332507 Exploratory - Trial result
Lymphoma
Ibrutinib (BTK inhibitor) + venetoclax (BCL-2 inhibitor) delivers 95% ORR and 40.2-mo mPFS in 1L non-blastoid MCL
Ibrutinib is an oral Bruton’s tyrosine kinase (BTK) inhibitor and venetoclax is an oral BCL-2 inhibitor; in the Phase 3 SYMPATICO open-label first-line cohort (NCT03112174), patients with previously untreated…
NCT03112174 - Trial result Spotlight
Lymphoma
Liso-cel (CD19 CAR-T) sustains 68% 3-year PFS in 3L+ follicular lymphoma
Lisocabtagene maraleucel (liso-cel) is an autologous anti-CD19 CAR-T cell therapy evaluated in the Phase 2 TRANSCEND FL study in relapsed/refractory follicular lymphoma after ≥2 prior systemic regimens including…
NCT04245839 - Trial result
Lymphoma
Epcoritamab (CD3×CD20 bispecific) exposure–response supports 48mg QW→Q2W→Q4W with lower CRS via 3-step ramp
Epcoritamab is a subcutaneous CD3×CD20 T-cell–engaging bispecific antibody; these updated population PK and exposure–response analyses across R/R follicular lymphoma (EPCORE NHL-1: ORR 82.0%, CR 62.5% [N=128]; EPCORE…
NCT03625037 - Trial result Spotlight
Lymphoma
Nivolumab (PD-1) + AVD lifts 3-year PFS in EBV+ and non–nodular sclerosis advanced cHL vs BV-AVD
Nivolumab-AVD (N-AVD) combines PD-1 blockade (nivolumab) with doxorubicin/vinblastine/dacarbazine chemotherapy, and in the Phase 3 SWOG S1826 frontline trial in stage III–IV classic Hodgkin lymphoma (NCT03907488),…
NCT03907488 - Trial result
Lymphoma
Pola (anti-CD79b ADC) + R-CHP Delivers 93% ORR/83% CR in Real-World Frontline DLBCL (Japan)
POLASTAR (jRCT1071220082) is a prospective, multicenter Japanese real-world study of polatuzumab vedotin (anti-CD79b antibody–drug conjugate delivering MMAE) plus rituximab, cyclophosphamide, doxorubicin, and…
- Trial result
Lymphoma
Englumafusp alfa (CD19–4-1BBL costimulator) + glofitamab (CD20×CD3) drives 56.6% CMR in R/R aggressive B‑NHL
Englumafusp alfa is an off-the-shelf CD19-targeting 4-1BBL co-stimulatory fusion protein designed to augment T-cell activation, combined here with glofitamab, a CD20×CD3 T-cell–engaging bispecific antibody, with…
NCT04077723 - Trial result
Lymphoma
Brentuximab vedotin (CD30 ADC) + AVEPC lifts PFS in pediatric stage IV cHL—except bone marrow-only disease
In COG AHOD1331 (NCT02166463), 2–21-year-olds with high-risk classic Hodgkin lymphoma and centrally PET-CT–confirmed stage IV disease (n=340; median age 15) were randomized to 5 cycles of ABVE-PC…
NCT02166463 - Trial result Spotlight
Lymphoma
Epcoritamab (CD3×CD20) + R2 delivers higher CR/OS vs real‑world R2/CIT in R/R follicular lymphoma
Epcoritamab is a subcutaneous CD3×CD20 bispecific antibody; here it was combined with lenalidomide (immunomodulatory agent) plus rituximab (anti‑CD20) as a chemotherapy-free regimen. In an adjusted comparative…
NCT04663347 - Trial result
Lymphoma
Epcoritamab (CD3×CD20 bispecific) hits early MRD-negativity in R/R FL—PFS signal strengthens by C3D1
Epcoritamab is a subcutaneous CD3×CD20 T-cell–engaging bispecific antibody evaluated as monotherapy in the EPCORE® NHL-1 Phase 1/2 study (NCT03625037) in relapsed/refractory follicular lymphoma after ≥2 prior lines;…
NCT03625037 - Trial result
Lymphoma
Ibrutinib (BTK inhibitor) + rituximab extends PFS but adds toxicity in chemo-ineligible 1L follicular lymphoma
Ibrutinib is an oral Bruton tyrosine kinase (BTK) inhibitor combined here with anti-CD20 rituximab as a chemotherapy-free first-line regimen. In the randomized, double-blind Phase 3 PERSPECTIVE trial (NCT02947347) in…
NCT02947347 - Trial result
Lymphoma
R2-based frontline FL: FLIPI24 flags high-risk patients with lower CR30 and 5-year PFS
FLIPI24 (a prognostic model for newly diagnosed follicular lymphoma) was evaluated in a pooled MD Anderson cohort of first-line, “chemo-free” immunotherapy regimens built around CD20 antibodies plus the…
NCT00695786 - Trial result
Lymphoma
Epcoritamab (CD3×CD20 bispecific) delivers 57.6% CR as chemo-free 1L option in anthracycline-ineligible DLBCL
Epcoritamab is a subcutaneous CD3×CD20 T-cell–engaging bispecific antibody evaluated as fixed-duration first-line therapy (± lenalidomide) in the open-label randomized Phase 2 EPCORE DLBCL-3 trial (NCT05660967) for…
NCT05660967
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.